GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acceleron Pharma Inc (NAS:XLRN) » Definitions » Operating Income

Acceleron Pharma (Acceleron Pharma) Operating Income : $-255.5 Mil (TTM As of Sep. 2021)


View and export this data going back to 2013. Start your Free Trial

What is Acceleron Pharma Operating Income?

Acceleron Pharma's Operating Income for the three months ended in Sep. 2021 was $-70.6 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2021 was $-255.5 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Acceleron Pharma's Operating Income for the three months ended in Sep. 2021 was $-70.6 Mil. Acceleron Pharma's Revenue for the three months ended in Sep. 2021 was $34.2 Mil. Therefore, Acceleron Pharma's Operating Margin % for the quarter that ended in Sep. 2021 was -206.53%.

Good Sign:

Acceleron Pharma Inc operating margin is expanding. Margin expansion is usually a good sign.

Acceleron Pharma's 5-Year average Growth Rate for Operating Margin % was 10.30% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Acceleron Pharma's annualized ROC % for the quarter that ended in Sep. 2021 was -182.99%. Acceleron Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2021 was -373.70%.


Acceleron Pharma Operating Income Historical Data

The historical data trend for Acceleron Pharma's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acceleron Pharma Operating Income Chart

Acceleron Pharma Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -66.11 -109.98 -124.41 -136.45 -167.31

Acceleron Pharma Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -39.23 -57.59 -63.60 -63.66 -70.63

Acceleron Pharma Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-255.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Acceleron Pharma  (NAS:XLRN) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Acceleron Pharma's annualized ROC % for the quarter that ended in Sep. 2021 is calculated as:

ROC % (Q: Sep. 2021 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2021 ) + Invested Capital (Q: Sep. 2021 ))/ count )
=-282.52 * ( 1 - -0.02% )/( (160.776 + 148.071)/ 2 )
=-282.576504/154.4235
=-182.99 %

where

Invested Capital(Q: Sep. 2021 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=787.848 - 49.208 - ( 590.569 - max(0, 57.371 - 696.608+590.569))
=148.071

Note: The Operating Income data used here is four times the quarterly (Sep. 2021) data.

2. Joel Greenblatt's definition of Return on Capital:

Acceleron Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2021 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2021 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2021  Q: Sep. 2021
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-282.52/( ( (27.379 + max(40.715, 0)) + (27.745 + max(55.361, 0)) )/ 2 )
=-282.52/( ( 68.094 + 83.106 )/ 2 )
=-282.52/75.6
=-373.70 %

where Working Capital is:

Working Capital(Q: Jun. 2021 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(27.937 + 0 + 64.704) - (51.926 + 0 + 0)
=40.715

Working Capital(Q: Sep. 2021 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(34.195 + 0 + 70.374) - (49.208 + 0 + 7.105427357601E-15)
=55.361

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2021) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Acceleron Pharma's Operating Margin % for the quarter that ended in Sep. 2021 is calculated as:

Operating Margin %=Operating Income (Q: Sep. 2021 )/Revenue (Q: Sep. 2021 )
=-70.63/34.199
=-206.53 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Acceleron Pharma Operating Income Related Terms

Thank you for viewing the detailed overview of Acceleron Pharma's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Acceleron Pharma (Acceleron Pharma) Business Description

Traded in Other Exchanges
N/A
Address
128 Sidney Street, Cambridge, MA, USA, 02139
Acceleron Pharma is a biotechnology company focused on the discovery, development, and commercialization of novel therapies. The company's research focuses on key natural regulators of cellular growth and repair. Acceleron generates its revenue through collaboration, licensing, and research arrangements with collaboration partners for the development and commercialization of therapeutic candidates. The company sometimes uses contract research organizations and research institutions outside the United States.
Executives
Sujay Kango officer: EVP, Chief Commercial Officer 1028 CHAMBERS COURT, BRIDGEWATER NJ 08807
Kevin F Mclaughlin officer: SVP, CFO and Treasurer C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Adam M Veness officer: SVP, General Counsel and Sec. C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Thomas A Mccourt director C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Karen L. Smith director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Joseph S Zakrzewski director 509 WATERVIEW PLACE, NEW HOPE PA 18938
Habib J Dable director, officer: CEO and President C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Terrence C Kearney director IN CARE OF HOSPIRA, INC., 275 NORTH FIELD DRIVE, LAKE FOREST IL 60045
Laura Hamill director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Bristol Myers Squibb Co 10 percent owner 430 E. 29TH STREET 14 FLOOR NEW YORK NY 10016
Celgene Corp /de/ 10 percent owner 86 MORRIS AVENUE, SUMMIT NJ 07901
Christopher Hite director C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Francois Nader director 550 HILLS DRIVE, BEDMINSTER NJ 07921
Jean George director CRITICAL THERAPEUTICS INC, 60 WESTVIEW STREET, LEXINGTON MA 02421
Kemal Malik director C/O ACCELERON PHARMA INC. 128 SIDNEY STREET CAMBRIDGE MA 02139

Acceleron Pharma (Acceleron Pharma) Headlines

From GuruFocus

Avoro Capital Issues Open Letter to Fellow Acceleron Pharma Shareholders

By Business Wire Business Wire 10-28-2021